• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.59% Nasdaq Up1.80%

    More On COX.PA

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Nicox SA (COX.PA)

    -Paris
    1.91 Up 0.02(0.79%) 11:35AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Nicox SA
    Drakkar 2 – Bâtiment D
    2405 route des Dolines
    Valbonne, 06506
    France - Map
    Phone: 33 4 97 24 53 00
    Fax: 33 4 97 24 53 99
    Website: http://www.nicox.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:124

    Business Summary 

    Nicox S.A., an ophthalmic company, develops and markets various ophthalmic products to enhance sight worldwide. The company offers AdenoPlus, an in vitro diagnostic medical device that aids in the diagnosis of acute conjunctivitis; and Xailin, a range of ocular products, such as medical devices, including ocular lubricants for dry eye symptoms and eyewash. Its products pipeline include Latanoprostene bunod, a drug-candidate based on its nitric oxide (NO)-donating research platform is in Phase III clinical trials for the treatment of glaucoma and ocular hypertension; and AC-170, a formulation of cetirizine, which has been completed Phase III clinical trials for the treatment of ocular itching associated with allergic conjunctivitis. The company’s products pipeline also comprise AzaSite to treat bacterial conjunctivitis; BromSite for the treatment of inflammation and prevention of pain after cataract surgery; Carragelose, an eye drop for viral conjunctivitis; and AC-155 for post-operative ocular inflammation and pain. In addition, its products pipeline consists of AAT for the combined detection of adenoviral and allergic conjunctivitis; OHT for the diagnosis of ocular herpes; next generation of NO-donors for eye disorder applications; and NO-donating glucocorticoids for the treatment of back and front of the eye disease. Further, the company’s products include Spleen Tyrosine Kinase and Janus Kinase inhibitors; Naproxcinod, an anti-inflammatory candidate for the relief of the signs and symptoms of osteoarthritis. It has collaboration with AstraZeneca, Pfizer, Merck, and Bausch + Lomb; and license agreement with InSite Vision Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Nicox SA

    Key Executives 
     PayExercised
    Mr. Michele Garufi , 61
    Co-Founder, Chairman and Chief Exec. Officer
    468.00KN/A
    Ms. Elizabeth Robinson ,
    Co-Founder and Pres of The Nicox Research Institute Srl
    N/AN/A
    Mrs. Sandrine Gestin ,
    Fin. Director
    N/AN/A
    Dr. Michael V.W. Bergamini Ph.D.,
    Chief Scientific Officer and Exec. VP
    N/AN/A
    Dr. Gavin Spencer ,
    Exec. VP of Corp. Devel.
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.